Overview

Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease

Status:
Recruiting

Trial end date:
2022-12-01

Target enrollment:

Participant gender:

Summary

To evaluate the clinical benefit of a post-operative adjuvant therapy combining radiotherapy + Nivolumab + Ipilimumab versus radiotherapy + Capecitabine in Triple Negative Breast Cancer (TNBC) patients with residual disease after neoadjuvant chemotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

Centre Leon Berard

Treatments:

Antibodies, Monoclonal
Capecitabine
Ipilimumab
Nivolumab